Symptomatic Effect of a Low-Dose Antacid Regimen in Reflux Oesophagitis

The symptomatic effect of a 2-week low-dose antacid tablet regimen was assessed in a prospective, double-blind, randomized, placebo-controlled, crossover trial in 47 patients with endoscopically verified reflux oesophagitis. During treatment with antacid there were lower global symptomatic scores (p < 0.05), less acid regurgitation (p < 0.05), and fewer days (p < 0.01) and nights (p < 0.05) with heartburn than during placebo therapy. Also, significantly more patients preferred antacid than placebo treatment (p <0.05). Thus, a low-dose antacid tablet regimen relieves symptoms significantly better than placebo in patients with reflux oesophagitis.